Marinomed focuses on growth after successful restructuring Marinomed plans to achieve an operating profit in 2025 Budesolv: innovation for the treatment of allergic rhinitis Switzerland as a stepping stone for global expansion Korneuburg, Austria, 27. March 2025 – Marinomed Biotech AG (VSE:MARI) has realigned its finances after a successful rest [ … ]

Marinomed Biotech AG: Successful completion of the sale of the Carragelose business to Unither Pharmaceuticals All requirements for closing the deal, including shareholders’ approval and ending of the restructuring proceedings, have been met Closing is associated with an upfront payment of EUR 5 million Additionally, Marinomed and Unither entere [ … ]

 Marinomed Biotech AG: Changes to the Management Board CFO Pascal Schmidt is resigning at the end of January 2025 Gabriele Ram, former Wienerberger AG, takes over the management of the finance department on an interim basis Restructuring proceedings successfully completed, financing of the Company secured by the sale of the Carragelose business  [ … ]

Marinomed Biotech AG: Restructuring proceedings successfully completed Restructuring proceedings formally ended by resolution of the Korneuburg regional court after meeting all necessary conditions, including unanimous approval of the restructuring plan Management Board takes over administration of Company from insolvency administrator Restructu [ … ]